BioStock published an article on 1 February 2021 about Follicum, which can be read in full below. For Follicum, one of this year’s main events will be the topline result from the ongoing phase IIa study with the company’s candidate FOL-005 for treatment of hair loss. The company announced on Thursday that all patients in […]
Presentation BioStock Life Science Summit 2020, November 18
Our drug candidate FOL-005 has demonstrated increased hair growth on both healthy individuals and on patients with alopecia in two clinical phase II trials, which both demonstrated good safety and efficacy.
Read moreFollicum AB today announced that all patients in the ongoing Phase IIa study with FOL-005 for the tr...
Follicum AB today announces that the European Patent Office (EPO) has approved the patent EP 3 618 8...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES,...
BioStock published an article on 1 February 2021 about Follicum, which can be read in full below. Fo...
BioStock published an article on 17 December 2020 about Follicum, which can be read in full below. A...
On 25 November 2020, Aktiespararna published their analysis of Follicum on their website. The analys...
Follicum will attend the BIO International Convention Digital Event on 10-11 & 14-18 June 2021....
Follicum will attend the World Congress for Hair Research in Melbourne (WCHR), Australia, on 22-25 A...
